Loading
TI
Teligent, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Pate R Carter, was filed 27 May 2021.
Teligent, Inc.: what insiders have been doing
Teligent, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Teligent, Inc. in twelve months, the latest record being from 20 July 2021.
Over the whole record (from 2016), the tally stands at 20 purchases and 10 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
36
Thresholds
n/a
Buy Volume
€352,298
20 ops. · all time
Sell Volume
€1M
10 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
Income statement
RevenueUS$39M
Gross profit-US$3.2M-8% margin
Net income-US$105.1M-269.3% margin
Last declaration on 20 July 2021
Declarations36 total
2,656 shares@ US$0.47100.0% of flowCommon StockSEC:0000352998-21-000007:1
7,835 shares0Common StockSEC:0000352998-21-000008:0
7,835 shares0Common StockSEC:0000352998-21-000007:0
30,000 shares@ US$0.5497100.0% of flowCommon StockSEC:0000352998-21-000006:0
Canonical exit: 25 Aug 2021 (T+90)
74,020 shares@ US$2.256513.8% of flowCommon StockSEC:0001213900-20-027008:0
13,251 shares@ US$2.24592.5% of flowCommon StockSEC:0001213900-20-027008:1
102,962 shares@ US$1.661514.1% of flowCommon StockSEC:0001213900-20-027008:2
18,432 shares@ US$1.65692.5% of flowCommon StockSEC:0001213900-20-027008:3
84,816 shares@ US$1.13368.0% of flowCommon StockSEC:0001213900-20-027008:4
15,184 shares@ US$1.12661.4% of flowCommon StockSEC:0001213900-20-027008:5
475,512 shares@ US$1.243548.9% of flowCommon StockSEC:0001213900-20-027008:6
85,106 shares@ US$1.24788.8% of flowCommon StockSEC:0001213900-20-027008:7
10,000 shares@ US$0.7005100.0% of flowCommon StockSEC:0001144204-19-029688:0
Canonical exit: 1 Sept 2019 (T+90)
25,000 shares@ US$0.6608100.0% of flowCommon StockSEC:0001144204-19-029389:0
Canonical exit: 29 Aug 2019 (T+90)
10,000 shares@ US$0.5885100.0% of flowCommon StockSEC:0001144204-19-029061:0
Canonical exit: 28 Aug 2019 (T+90)
20,000 shares@ US$0.6452100.0% of flowCommon StockSEC:0001144204-19-029305:0
Canonical exit: 29 Aug 2019 (T+90)
20,000 shares@ US$0.658348.9% of flowCommon StockSEC:0001144204-19-029304:0
Canonical exit: 29 Aug 2019 (T+90)
25,000 shares@ US$0.69347.8% of flowCommon StockSEC:0001144204-19-028060:0
Canonical exit: 21 Aug 2019 (T+90)
20,000 shares@ US$0.690751.1% of flowCommon StockSEC:0001144204-19-028059:0
Canonical exit: 21 Aug 2019 (T+90)
12,000 shares@ US$1.78100.0% of flowCommon StockSEC:0001144204-18-064592:0
Canonical exit: 14 Mar 2019 (T+90)
10,000 shares@ US$1.82100.0% of flowCommon StockSEC:0001144204-18-064591:0
Canonical exit: 14 Mar 2019 (T+90)
8,333 shares0Common StockSEC:0001144204-18-054833:0
5,000 shares0Common StockSEC:0001144204-18-054834:0
52,700 shares@ US$4.0092.0% of flowCommon StockSEC:0001144204-18-048103:0
100 shares@ US$4.010.2% of flowCommon StockSEC:0001144204-18-048103:1
25 of 36 declarations
About Teligent, Inc.
Teligent, Inc. (ticker TLGT) was a U.S.-based specialty pharmaceutical company that was listed on the NASDAQ in the United States. Historically, the company focused on generic topical pharmaceuticals, branded generics, and generic injectable products, and it also expanded into more complex and ophthalmic dosage forms. In addition to branded-and-generic commercialization, Teligent operated a contract manufacturing and development business for pharmaceutical, OTC, and cosmetic customers. The company was incorporated in 1977 and was formerly known as IGI Laboratories before adopting the Teligent name in 2015. Its principal executive office and manufacturing footprint were in Buena, New Jersey, with additional locations in Canada and Estonia. ([sec.gov](https://www.sec.gov/Archives/edgar/data/352998/000162828020004877/tlgt-20191231.htm?utm_source=openai))
From a business-model perspective, Teligent competed in the specialty generics market, where manufacturing quality, regulatory execution, and product approvals are central to competitiveness. The company emphasized its expertise in topical semi-solids and liquid formulations used in dermatology, including treatments associated with eczema, psoriasis, and dermatitis. Its commercial reach extended across the United States and Canada through wholesalers, pharmacy chains, distributors, and group purchasing organizations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/352998/000162828020004877/tlgt-20191231.htm?utm_source=openai))
Read moreShow less
Strategically, management sought to broaden the company beyond its core topical franchise through what it called the “TICO” strategy, a push into injectable, complex, and ophthalmic generics. That approach was intended to leverage existing formulation and manufacturing capabilities while reducing reliance on a narrow product mix. In competitive terms, Teligent operated in a crowded market dominated by larger, better-capitalized generic drug makers, as well as specialized niche manufacturers. Its value proposition rested on in-house development, filling, packaging, and a relatively diversified formulation platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/352998/000162828020004877/tlgt-20191231.htm?utm_source=openai))
Recent history is dominated by distress and restructuring rather than growth. Teligent filed for Chapter 11 protection in October 2021 to pursue a sale process, and later filings and market references indicate the company entered a liquidation path in 2022. More recent market-profile sources describe the business as out of operation, which means TLGT is now primarily relevant as a historical SEC and insider-reporting name rather than an active listed operating company. For investors, this is an important distinction: while the ticker and legacy filings remain searchable, the company itself no longer appears to be functioning as a going concern. ([sec.gov](https://www.sec.gov/Archives/edgar/data/352998/000110465921126768/tm2129875d1_8k.htm?utm_source=openai))
